Sino Biopharmaceutical Ltd. financial statements, including revenue, expenses, profit, and loss
The total revenue of SBHMY for the last semiannual is 1.51 B USD, and it's 31.53% lower compared to the previous semiannual. The net income of H2 23 is 148.27 M USD.